Pixurvi Moves Closer to Market in France
Cell Therapeutics is reporting that the Transparency Commission of the French National Health Authority has granted market access to CTI for its oncology product Pixurvi as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Join the discussion below, or Read more at Lymphoma Info.
#1 Aug 21, 2013
hey you out there good quality steroids
at good price and without prescription.burn it it out..
contact at [email protected] for details and quotes tganks
Add your comments below
|Benign tumor||Mar 17||Bharath k||1|
|Myriad Genetics Announces an Assay that Identif...||Feb '17||Purplemouse2||8|
|Holzer receives donation from Fruth pharmacies||Jan '17||Steve||1|
|New team players: Palliative care specialists f...||Jan '17||Death||3|
|Should Gerard Depardieu Have Worn Adult Diapers... (Aug '11)||Jan '17||kirton||2|
|Endothelial SCUBE2 Interacts With VEGFR2 and Re...||Jan '17||TW_sugar_daddio||3|
|Few Care for the Undocumented With Breast Cancer||Dec '16||HOLLA ISABELLA||2|
Find what you want!
Search Oncology Forum Now
Copyright © 2017 Topix LLC